Jefferies Initiates Coverage On Candel Therapeutics with Buy Rating, Announces Price Target of $25
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsInitiationPrice Target
Jefferies analyst Maury Raycroft initiates coverage on Candel Therapeutics (NASDAQ:CADL) with a Buy rating and announces Price Target of $25.
Jefferies analyst Maury Raycroft initiates coverage on Candel Therapeutics (NASDAQ:CADL) with a Buy rating and announces Price Target of $25.